List of Neovacs patents

List of Neovacs patents

List of Mochida Pharmaceutical patents

List of Toray Industries patents

List of energetiq technology, inc. patents

List of musical instrument manufacturing patents

List of AI distributed ledger companies

Patents where

Current Assignee

Name

is

‌

Neovacs

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 7351554 Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's	Patent 7351554 was granted and assigned to Neovacs on April, 2008 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	7351554	April 1, 2008
	‌ US Patent 7504479 Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses	Patent 7504479 was granted and assigned to Neovacs on March, 2009 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	7504479	March 17, 2009
	‌ US Patent 9993565 Method for treating IFNalpha related conditions	Patent 9993565 was granted and assigned to Neovacs on June, 2018 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	9993565	June 12, 2018
	‌ US Patent 8679483 High-yield method for the production of human antibodies blocking the biological activity of a human cytokine	Patent 8679483 was granted and assigned to Neovacs on March, 2014 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	8679483	March 25, 2014
	‌ US Patent 8101165 Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors	Patent 8101165 was granted and assigned to Neovacs on January, 2012 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	8101165	January 24, 2012
	‌ US Patent 7972603 Stable immunogenic product comprising antigenic heterocomplexes	Patent 7972603 was granted and assigned to Neovacs on July, 2011 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	7972603	July 5, 2011
	‌ US Patent 7887811 Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein	Patent 7887811 was granted and assigned to Neovacs on February, 2011 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	7887811	February 15, 2011
	‌ US Patent 8697047 Stable immunogenic product comprising antigenic heterocomplexes	Patent 8697047 was granted and assigned to Neovacs on April, 2014 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	8697047	April 15, 2014
	‌ US Patent 7314629 Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus	Patent 7314629 was granted and assigned to Neovacs on January, 2008 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	7314629	January 1, 2008
	‌ US Patent 8372388 Method for preparing a stable TNF-α vaccine	Patent 8372388 was granted and assigned to Neovacs on February, 2013 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	8372388	February 12, 2013
	‌ US Patent 7015016 Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's	Patent 7015016 was granted and assigned to Neovacs on March, 2006 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	7015016	March 21, 2006
	‌ US Patent 7022482 Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses	Patent 7022482 was granted and assigned to Neovacs on April, 2006 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	7022482	April 4, 2006
	‌ US Patent 6878370 Chemically modified TNF-α	Patent 6878370 was granted and assigned to Neovacs on April, 2005 by the United States Patent and Trademark Office.		‌ Neovacs		United States Patent and Trademark Office	6878370	April 12, 2005

13 results

0 selected

13 results

0 selected